Dr. Huang Xiaojun
Director, Peking University Institute of Hematology; Chief Physician; Professor; Academician of the Chinese Academy of Engineering
Where they practice, who they consult.
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing
- 40+ years in hematology and transplantation
- English, Mandarin
What they personally lead.
Training and recognition
Architect of the "Beijing Protocol" for haploidentical HSCT (G-CSF + ATG conditioning) which made transplant accessible without a fully matched donor and is now used worldwide; Academician of the Chinese Academy of Engineering; past chair of the Chinese Society of Hematology; lead/senior author on landmark publications in Blood, The Lancet Oncology, and Journal of Clinical Oncology comparing haplo-HSCT to matched sibling transplant
What to expect
First-choice consultation for adult and pediatric patients with high-risk AML, ALL, MDS, or aplastic anemia who lack a matched sibling or unrelated donor. Peking University People's Hospital performs more than 1,000 allogeneic transplants per year, the majority haploidentical.
Check the public record
Look up publications, citations, and academic profile on independent platforms before reaching out.
Results are automated searches and may include other individuals with similar names.
Ask the AI or request a coordinator.
The AI can compare Huang Xiaojun's background to other specialists in Beijing. A coordinator can confirm appointment availability and English-language support.
Information is provided for reference only and may not reflect current conditions. Verify directly with the hospital before making decisions.